Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Standard BioTools Q1 EPS $(0.07), Inline, Sales $40.80M Beat $40.10M Estimate

Author: Benzinga Newsdesk | May 06, 2025 04:02pm
Standard BioTools (NASDAQ:LAB) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 74.07 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $40.80 million which beat the analyst consensus estimate of $40.10 million by 1.75 percent. This is a 10.41 percent decrease over sales of $45.54 million the same period last year.

Posted In: LAB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist